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In this special issue of BJR, we focus on the application
of nanoparticles (NPs) for diagnostic imaging and radio-
therapy. Nanotechnology in medicine is a rapidly expanding
area with a range of clinical impacts. Driving research in
this area has been the rapid development of novel nano-
agents for targeted delivery of drugs in many disease types
including cancer. For cancer, and speciﬁcally radiation-
based therapies, the focus has been less on drug delivery
but more on the potential of metal-based NPs to act as
theranostics. Theranostic agents are designed to combine
diagnostic information with therapy delivery, with metals,
such as gold and gadolinium, being able to act both as
image contrast agents for diagnostic imaging and radio-
sensitizers for therapy. An article by Hainfeld et al, in BJR
in 2006,1 was one of the ﬁrst articles to highlight the promise
of gold NPs, and a more recent review2 highlighted the
potential of gadolinium-based NPs as theranostics. It is now
timely to highlight some of the key ongoing challenges in
this area with a series of reviews from internationally re-
spected NP researchers.
In an introductory commentary (doi: 10.1259/bjr.20150171),
the key potential advantages of NPs combined with radi-
ation are highlighted. This is the ability to expand the
therapeutic window by targeting radiosensitization to the
tumour and not normal tissues. This radiosensitization will
be driven by both physical interactions of radiation with
the NPs and biological parameters. To understand the physics
of energy interactions with metal-based NPs, and make
predictions regarding their potential dose-enhancement
effects, radiation transport calculations including Monte
Carlo modelling approaches have a key role to play, and
these need to be applied for a range of monoenergetic and
clinical beams. The biological response is heavily inﬂu-
enced by the design and pharmacokinetic properties of
the NPs for use in combination with radiotherapy. It is
important to consider aspects of administration, distri-
bution, metabolism and expulsion which are inﬂuenced
by alterations in NPs such as loss of colloidal stability,
protein adsorption and chemical transformation.
To accurately quantify the spatial distribution of NPs, novel
imaging technologies have to be utilized for in vitro studies.
There are signiﬁcant challenges in imaging at the NP scale
and validating their uptake, distribution and localization
in mammalian cells. Although electron microscopy is still
the standard validation approach, it has practical limi-
tations. One particular approach showing potential is
the use of multiphoton plasmon resonance imaging
(doi: 10.1259/bjr.20150170). Cell-tracking approaches have
the potential to play an increasing important role in pre-
clinical and clinical studies. There are signiﬁcant gains to
be made using labelling with NPs for in vivo applications
for the application of cell-tracking approaches. Developing
approaches here include the use of superparamagentic
iron oxide and paramagnetic gadolinium and manganese
NPs for MRI and more recently 19F-labelling approaches
(doi: 10.1259/bjr.20150375).
NP approaches can also pay a role in Nuclear Medicine,
and several approaches are available for combining
NPs and radioactive molecular imaging in translational re-
search and clinical trials. The speciﬁc labelling of NPs with
gamma-emitting radionuclides for single-photon emission
CT (SPECT) imaging, positron-emitting radioisotopes for
positron emission tomography (PET) and multimodal
nuclear imaging approaches are all currently being tested
(doi: 10.1259/bjr.20150185). Despite the great potential of
NPs in diagnostic imaging currently only one agent, iron
oxide NPs, is being utilized clinically. The enhanced per-
meability and retention effect is key to the delivery of di-
agnostic NP agents, and the tunability of these for use with
MRI, CT, optical imaging, photoacoustic imaging, PET
and SPECT needs to be optimized to deliver clinical po-
tential for nanotheranostics and image-guided drug de-
livery (doi: 10.1259/bjr.20150207).
In the therapeutic space, only one metal-based NP is in a Phase 1
clinical trial at present (Pottier et al); however, many tumour
types could potentially beneﬁt from combinations of NPs
with radiotherapy if the potential of an increased therapeutic
window can be delivered. For example, in prostate cancer,
several approaches are currently being evaluated in pre-clinical
studies for combinations of NPs with not only external
beam radiotherapy but also with brachytherapy (doi: 10.1259/
bjr.20150256).
The future for the application of NPs holds signiﬁcant potential,
and we hope that this selection of articles will give BJR readers
a taste of the challenges and opportunities for NPs to revolu-
tionize diagnostic imaging and radiotherapy.
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